Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells

Claudio Fortis, Elisabetta Ferrero, Carlo Besana, Mauro Biffi, Silvia Heltai, Laura Galli, Anna Borri, Alisa Schoenheit, Claudio Rugarli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open, non-randomized, phase II trial. Immediately before each rIL-2 infusion and during the last day of infusion, immunological tests were performed on the patients' peripheral blood mononuclear cells. During rIL-2 infusion we have observed a slight increase of the spontaneous cell proliferation and of natural killer (NK) and LAK activity; phenotypic analysis showed a significant decrease in the CD4+ T-lymphocyte subset, both in percentage and in absolute number. Conversely, before each cycle CD4+ cells increased when compared to basal values. No significant variations were observed in the CD8+ T-lymphocyte subset. Furthermore, a significant increase of the NK cells (CD3- CD56+ CD16+) was evident during rIL-2 infusion.

Original languageEnglish
Pages (from-to)161-166
Number of pages6
JournalCancer Immunology, Immunotherapy
Volume32
Issue number3
DOIs
Publication statusPublished - May 1990

Fingerprint

Lymphokine-Activated Killer Cells
Kidney Neoplasms
Interleukin-2
Blood Cells
T-Lymphocyte Subsets
Immunologic Tests
Lymphokines
Natural Killer Cells
Cell Cycle
Animal Models
Cell Proliferation
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients : I. phenotypic and functional analysis of the peripheral blood mononuclear cells. / Fortis, Claudio; Ferrero, Elisabetta; Besana, Carlo; Biffi, Mauro; Heltai, Silvia; Galli, Laura; Borri, Anna; Schoenheit, Alisa; Rugarli, Claudio.

In: Cancer Immunology, Immunotherapy, Vol. 32, No. 3, 05.1990, p. 161-166.

Research output: Contribution to journalArticle

Fortis, Claudio ; Ferrero, Elisabetta ; Besana, Carlo ; Biffi, Mauro ; Heltai, Silvia ; Galli, Laura ; Borri, Anna ; Schoenheit, Alisa ; Rugarli, Claudio. / Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients : I. phenotypic and functional analysis of the peripheral blood mononuclear cells. In: Cancer Immunology, Immunotherapy. 1990 ; Vol. 32, No. 3. pp. 161-166.
@article{ccf895b3fd6842b7901a3a2e151db6fb,
title = "Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells",
abstract = "The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open, non-randomized, phase II trial. Immediately before each rIL-2 infusion and during the last day of infusion, immunological tests were performed on the patients' peripheral blood mononuclear cells. During rIL-2 infusion we have observed a slight increase of the spontaneous cell proliferation and of natural killer (NK) and LAK activity; phenotypic analysis showed a significant decrease in the CD4+ T-lymphocyte subset, both in percentage and in absolute number. Conversely, before each cycle CD4+ cells increased when compared to basal values. No significant variations were observed in the CD8+ T-lymphocyte subset. Furthermore, a significant increase of the NK cells (CD3- CD56+ CD16+) was evident during rIL-2 infusion.",
author = "Claudio Fortis and Elisabetta Ferrero and Carlo Besana and Mauro Biffi and Silvia Heltai and Laura Galli and Anna Borri and Alisa Schoenheit and Claudio Rugarli",
year = "1990",
month = "5",
doi = "10.1007/BF01771451",
language = "English",
volume = "32",
pages = "161--166",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients

T2 - I. phenotypic and functional analysis of the peripheral blood mononuclear cells

AU - Fortis, Claudio

AU - Ferrero, Elisabetta

AU - Besana, Carlo

AU - Biffi, Mauro

AU - Heltai, Silvia

AU - Galli, Laura

AU - Borri, Anna

AU - Schoenheit, Alisa

AU - Rugarli, Claudio

PY - 1990/5

Y1 - 1990/5

N2 - The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open, non-randomized, phase II trial. Immediately before each rIL-2 infusion and during the last day of infusion, immunological tests were performed on the patients' peripheral blood mononuclear cells. During rIL-2 infusion we have observed a slight increase of the spontaneous cell proliferation and of natural killer (NK) and LAK activity; phenotypic analysis showed a significant decrease in the CD4+ T-lymphocyte subset, both in percentage and in absolute number. Conversely, before each cycle CD4+ cells increased when compared to basal values. No significant variations were observed in the CD8+ T-lymphocyte subset. Furthermore, a significant increase of the NK cells (CD3- CD56+ CD16+) was evident during rIL-2 infusion.

AB - The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open, non-randomized, phase II trial. Immediately before each rIL-2 infusion and during the last day of infusion, immunological tests were performed on the patients' peripheral blood mononuclear cells. During rIL-2 infusion we have observed a slight increase of the spontaneous cell proliferation and of natural killer (NK) and LAK activity; phenotypic analysis showed a significant decrease in the CD4+ T-lymphocyte subset, both in percentage and in absolute number. Conversely, before each cycle CD4+ cells increased when compared to basal values. No significant variations were observed in the CD8+ T-lymphocyte subset. Furthermore, a significant increase of the NK cells (CD3- CD56+ CD16+) was evident during rIL-2 infusion.

UR - http://www.scopus.com/inward/record.url?scp=0025633477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025633477&partnerID=8YFLogxK

U2 - 10.1007/BF01771451

DO - 10.1007/BF01771451

M3 - Article

C2 - 2289209

AN - SCOPUS:0025633477

VL - 32

SP - 161

EP - 166

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -